Anzeige
Mehr »
Sonntag, 03.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EG3E | ISIN: GG00BMFG5F62 | Ticker-Symbol: OK11
Stuttgart
01.08.25 | 10:22
2,060 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
OKYO PHARMA LIMITED Chart 1 Jahr
5-Tage-Chart
OKYO PHARMA LIMITED 5-Tage-Chart

Aktuelle News zur OKYO PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.07.OKYO Pharma Ltd - 20-F, Annual and transition report of foreign private issuers2
OKYO PHARMA Aktie jetzt für 0€ handeln
17.07.OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain297LONDON and NEW YORK, July 17, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic...
► Artikel lesen
17.07.OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data2
16.07.OKYO Pharma Stock Rises 8% On Positive Phase 2 Trial Results For Neuropathic Corneal Pain Therapy3
16.07.OKYO Pharma reports results from Urcosimod trial2
16.07.OKYO Pharma meldet positive Top-Line-Ergebnisse aus Phase-2-Studie mit Urcosimod/n-
16.07.OKYO Pharma Ltd - 6-K, Report of foreign issuer1
16.07.Positive Studiendaten zu Augenschmerzmittel beflügeln OKYO-Pharma-Aktie1
16.07.OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain164After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), demonstrating...
► Artikel lesen
16.07.OKYO Pharma stock surges after positive Phase 2 results for eye pain drug2
11.06.Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited337Raising Price Target Due to Fundamental Drivers BALTIMORE, MD / ACCESS Newswire / June 11, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap...
► Artikel lesen
11.06.OKYO Pharma to Present at the Bio International Convention262LONDON and NEW YORK, June 11, 2025), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA...
► Artikel lesen
11.06.OKYO Pharma Ltd - 6-K, Report of foreign issuer3
19.05.OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit268LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic...
► Artikel lesen
19.05.OKYO Pharma Ltd - 6-K, Report of foreign issuer3
06.05.Okyo Pharma - Targeting underserved corneal diseases190OKYO Pharma is advancing lead candidate urcosimod (previously OK-101) for neuropathic corneal pain (NCP), an area of unmet need with no approved treatment, as well as for inflammatory dry eye disease...
► Artikel lesen
01.05.OKYO Pharma LTD: FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain343LONDON and NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to...
► Artikel lesen
30.04.OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain340Urcosimod phase 2 trial treating Neuropathic Corneal Pain ("NCP") patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial.OKYO Pharma plans...
► Artikel lesen
30.04.OKYO Pharma Ltd - 6-K, Report of foreign issuer2
31.03.OKYO Pharma reports long-term benefits of its neuropathic corneal pain treatment5
Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1